Issue navigation
Volume 16, Issue S1, May 1998
Stem Cells
Articles
Cover art: The watercolor drawings of james homer wright
Stem Cells, Volume 16, Issue S1, May 1998, Pages ix–x, https://doi.org/10.1002/stem.5530160701
Prefaces
Preface
Stem Cells, Volume 16, Issue S1, May 1998, Pages xi–xii, https://doi.org/10.1002/stem.5530160702
Keynotes
The molecular control of hematopoiesis: Progress and problems with gene manipulation
Stem Cells, Volume 16, Issue S1, May 1998, Pages 1–9, https://doi.org/10.1002/stem.5530160703
Thrombopoietin: Structure, Function and Mechanism of Actions
Native thrombopoietin: Structure and function
Stem Cells, Volume 16, Issue S1, May 1998, Pages 11–19, https://doi.org/10.1002/stem.5530160704
Peptide agonists of the thrombopoietin receptor
Stem Cells, Volume 16, Issue S1, May 1998, Pages 21–29, https://doi.org/10.1002/stem.5530160705
IL-3 does not contribute to platelet production in c-Mpl-deficient mice
Stem Cells, Volume 16, Issue S1, May 1998, Pages 31–36, https://doi.org/10.1002/stem.5530160706
Compared effects of Mpl ligand and other cytokines on human MK differentiation
Stem Cells, Volume 16, Issue S1, May 1998, Pages 37–51, https://doi.org/10.1002/stem.5530160707
The role of IL-11 in hematopoiesis as revealed by a targeted mutation of its receptor
Stem Cells, Volume 16, Issue S1, May 1998, Pages 53–65, https://doi.org/10.1002/stem.5530160708
Biologyo F Megakaryocdyitfef Erentlatmiaotnur, Ation and Platelet Release Actions
Use of the zebrafish (danio rerio) to define hematopoiesis
Stem Cells, Volume 16, Issue S1, May 1998, Pages 67–78, https://doi.org/10.1002/stem.5530160709
Transcription factor GATA-1 in megakaryocyte development
Stem Cells, Volume 16, Issue S1, May 1998, Pages 79–83, https://doi.org/10.1002/stem.5530160710
Analysis of hematopoietic stem cell reprogramming with toxigenicity
Stem Cells, Volume 16, Issue S1, May 1998, Pages 85–89, https://doi.org/10.1002/stem.5530160711
Cellular and molecular biology of megakaryocyte differentiation in the absence of lineage-restricted transcription factors
Stem Cells, Volume 16, Issue S1, May 1998, Pages 91–95, https://doi.org/10.1002/stem.5530160712
Cyclin D3 and megakaryocyte development: Exploration of a transgenic phenotype
Stem Cells, Volume 16, Issue S1, May 1998, Pages 97–106, https://doi.org/10.1002/stem.5530160713
The Effects of Mpl Ligand in Animal Models
Effects of mpl ligands on platelet production and function in nonhuman primates
Stem Cells, Volume 16, Issue S1, May 1998, Pages 107–119, https://doi.org/10.1002/stem.5530160714
The effect of MGDF on platelet function and thrombosis in animal models
Stem Cells, Volume 16, Issue S1, May 1998, Pages 121–126, https://doi.org/10.1002/stem.5530160715
The efficacy of recombinant tpo in murine and nonhuman primate models for myelosuppression and stem cell transplantation
Stem Cells, Volume 16, Issue S1, May 1998, Pages 127–141, https://doi.org/10.1002/stem.5530160716
The combined administration of daniplestim and mpl ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression
Stem Cells, Volume 16, Issue S1, May 1998, Pages 143–154, https://doi.org/10.1002/stem.5530160717
Pathologicadli Sorderofs of Egakaryocytopoiesis
Myelofibrosis: Experimental models and human studies
Stem Cells, Volume 16, Issue S1, May 1998, Pages 155–164, https://doi.org/10.1002/stem.5530160718
Endogenous TPO (eTPO) levels in health and disease: Possible clues for therapeutic intervention
Stem Cells, Volume 16, Issue S1, May 1998, Pages 165–175, https://doi.org/10.1002/stem.5530160719
Defective c-Mpl signaling in the syndrome of thrombocytopenia with absent radii
Stem Cells, Volume 16, Issue S1, May 1998, Pages 177–184, https://doi.org/10.1002/stem.5530160720
A novel thrombopoietin signaling defect in polycythemia vera platelets
Stem Cells, Volume 16, Issue S1, May 1998, Pages 185–192, https://doi.org/10.1002/stem.5530160721
Clinical Hplications of Mpll Igand and Other Thrombopoiecyttiock Lnes in Chemotherapy, Bone Marrow Transplantaatnido Ntr Ansfusimoend Icines
Overview of the safety and biologic effects of peg-rhumgdf in clinical trials
Stem Cells, Volume 16, Issue S1, May 1998, Pages 193–198, https://doi.org/10.1002/stem.5530160722
Recombinant human thrombopoietin clinical development
Stem Cells, Volume 16, Issue S1, May 1998, Pages 199–206, https://doi.org/10.1002/stem.5530160723
FDA licensure of neumega® to prevent severe chemotherapy-induced thrombocytopenia
Stem Cells, Volume 16, Issue S1, May 1998, Pages 207–223, https://doi.org/10.1002/stem.5530160724
Early australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor
Stem Cells, Volume 16, Issue S1, May 1998, Pages 225–229, https://doi.org/10.1002/stem.5530160725
The use of PEG-rHuMGDF in platelet apheresis
Stem Cells, Volume 16, Issue S1, May 1998, Pages 231–242, https://doi.org/10.1002/stem.5530160726
The role of c-Mpl ligands in the expansion of cord blood hematopoietic progenitors
Stem Cells, Volume 16, Issue S1, May 1998, Pages 243–248, https://doi.org/10.1002/stem.5530160727
Opportunities for the use of thrombopoietic growth factors
Stem Cells, Volume 16, Issue S1, May 1998, Pages 249–253, https://doi.org/10.1002/stem.5530160728
Contributors
Contributors
Stem Cells, Volume 16, Issue S1, May 1998, Pages 255–257, https://doi.org/10.1002/stem.5530160729
